Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Cancer Vaccines CRS-207 and GVAX Pancreas for Metastatic Pancreatic Adenocarcinoma
This study is ongoing, but not recruiting participants.
Study NCT01417000 Information provided by Aduro BioTech, Inc.
First Received on August 10, 2011. Last Updated on November 12, 2012
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Pancreatic Cancer
Additional conditions recognized in this trial
Adenocarcinoma
Adenocarcinoma, Mucinous
Pancreatic Neoplasms
More general conditions related to this trial
Carcinoma
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Cystic, Mucinous, and Serous
Neoplasms, Glandular and Epithelial
Pancreatic Diseases
Interventions listed in this trial
GVAX Pancreas and Cyclophosphamide
Additional drug interventions recognized in this trial
Cyclophosphamide
Pancreatin
Pancrelipase
More general drug interventions related to this trial
Alkylating Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antirheumatic Agents
Gastrointestinal Agents
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Aduro BioTech, Inc.
Johns Hopkins University
Back to top of Main Content
